Phase III Study of Lampalizumab in patients with geographic atrophy secondary to AMD 31/03/2014

Description

Phase III, Multi-center, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of Lampalizumab intravitreal injections Administered Monthly for 24 Months in Patients with Geographic Atrophy Secondary to AMD.

If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information on trials at research projects.

Author

Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal